Pre-Made Setoxaximab biosimilar, Whole Mab: Anti-Shiga Toxin Type 2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Setoxaximab benchmark antibody ( Whole mAb, anti-Shiga Toxin Type 2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-516
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Setoxaximab biosimilar, Whole Mab: Anti-Shiga Toxin Type 2 therapeutic antibody |
---|---|
INN Name | Setoxaximab |
Target | Shiga Toxin Type 2 |
Format | Whole mAb |
Derivation | Chimeric (Mouse/Human) |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Discontinued |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2012 |
Year Recommended | 2013 |
Companies | Sunol Molecular Corporation,Uniformed Services University of the Health Sciences,BELLUS Health,Taro Pharmaceuticals Inc |
Conditions Approved | NA |
Conditions Active | NA |
Conditions Discontinued | Haemolytic uraemic syndrome,Shiga-toxigenic Escherichia coli infections |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | Shiga Toxin Type 2 |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide
![](https://www.genemedi.com/wp-content/uploads/2022/07/quality.webp)